SPECT myocardial perfusion imaging identifies myocardial ischemia in patients with a history of COVID-19 without coronary artery disease

Çap, Murat; Bilge, Önder; Gündoğan, Cihan; Tatlı, İsmail; Öztürk, Cansu; Taştan, Ercan; Kepenek, Ferat; Işık, Ferhat; Okşul, Metin; Oktay, Mesut; Akyüz, Abdurrahman; Erdoğan, Emrah; Burak, Cengiz; Süleymanoğlu, Muhammed; Karagöz, Ali; Tanboğa, İbrahi̇m Hali̇l

doi:10.1007/s10554-021-02477-9

Cited by 11 publications

(20 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Persistent symptoms may include hypotension, tachycardia, palpitations, dyspnoea and arrhythmias 47 , 48 , 49 , 50 , with some requiring hospital readmission 51 . There are increased risks of incident cardiovascular disease, such as cerebrovascular disorders (stroke/transient ischaemic attacks), dysrhythmia (atrial fibrillation/sinus tachycardia), ischaemic heart disease (acute coronary disease/myocardial infarction/angina), thromboembolic disease (pulmonary embolism/deep vein thrombosis), heart failure, pericarditis, myocarditis, cardiac arrest and cardiogenic shock 49 , 52 , 53 , 54 , 55 , 56 . Long-term sequelae may include increased cardiometabolic demand, myocardial fibrosis or scarring, arrhythmias, tachycardia and autonomic dysfunction, as in POTS described above 6 .…”

Section: Discussionmentioning

confidence: 99%

The Provision of Dental Care to COVID-19 Survivors: A Concise Review

Ngeow

Liszen

Yang

et al. 2022

International Dental Journal

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The Provision of Dental Care to COVID-19 Survivors: A Concise Review

Ngeow

Liszen

Yang

et al. 2022

International Dental Journal

View full text Add to dashboard Cite

“…Of included studies 46% (13/28) included both hospitalised and nonhospitalised populations, while 29% (8/28) followed up people who were not hospitalised, and 25% (7/28) were cohorts of hospitalised patient post-discharge. Control groups included population testing negative (39.3%, 11/28) [34,39,40,44,46,47,51,55,56,59,61], healthcare workers testing negative (21.4%, 6/28) [35,37,38,42,43,52], historic cohorts (14.3%, 4/28) [45,49,53,58], healthy controls (10.7%, 3/28) [41,48,54], both negative and untested population (7.1%, 2/28) [50,60], and cohorts with influenza (3.5%, 1/28) [57] and sepsis (3.5%, 1/28) [36]. Only 32% (9/28) of studies reported ethnicity of the participants [34,39,41,49,54,56,57,59,61].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…The longest follow-up period in any study was a mean of 419.8 (standard deviation: 49.4) days postdiagnosis. Studies followed participants up with various methods, including 50% (14/28) with an outpatient visit consultation [34,36,42,43,[46][47][48][49][52][53][54][55]58], followed by questionnaires, including online (21.4%, 6/28) [37,41,50,51,60,61], phone (14.3%, 4/28) [35,38,40,45], and letter (3.6%, 1/28) [39], while 11% (3/28) used electronic health records (EHRs) data analysis [56,57,59]. Tools used to assess signs and symptoms varied between studies.…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…The risk of bias and quality of evidence in individual studies varied, with 17.9% (5/28) of studies assessed as low risk of bias [46,56,57,60,61], 71.4% (20/28) as medium [34][35][36][37][38][39][40][42][43][44][45]47,[49][50][51][53][54][55]58,59], and 10.7% (3/28) as high [41,48,52] (supplement 4). The maximum and minimum scores achieved were 3 and 8 points, respectively.…”

Section: Risk Of Biasmentioning

confidence: 99%

“…[34] Two studies reported associations between a confirmed prior Covid-19 infection and persisting myocardial involvement, compared to a non-Covid-19 control. [48,55] Another study found evidence of higher sustained endothelial cell activation, coagulation activation, and inflammation between the Covid-19 and control cohorts, but with no difference for macrovascular dysfunction three months after acute Covid-19. [58] One study reported, three months after hospital discharge, right ventricular function was mildly impaired, likely associated with pulmonary pathology, and diastolic dysfunction was twice as common in Covid-19 patients compared to controls; however, left ventricular dysfunction is not common.…”

Section: Imaging and Diagnosticsmentioning

confidence: 99%

See 2 more Smart Citations

Characterising Long Covid: a living systematic review update with controlled studies

Michelen

Sigfrid

Kartsonaki

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: The clinical sequelae (Long Covid) of acute Covid-19 are recognised globally, yet the risk of developing them is unknown. Methods: A living systematic review (second version). Bibliographical records from the C19 Living Map Long Covid segment (22nd February 2022), Medline, CINAHL, Global Health, WHO Covid-19 database, LitCOVID, and Google Scholar (18th November 2021). We included studies with at least 100 people at 12 weeks or more post-Covid-19 onset and with a control group without confirmed Covid-19. Risk of bias was assessed using the Newcastle-Ottawa scale. Symptoms are aligned with the Post Covid-19 Condition Core Outcome Set. We present descriptive statistics and use meta-analysis to estimate the relative risk of experiencing Long Covid. Results Twenty-eight studies were included: 20 cohort, five case-controls, three cross-sectional. Studies reported on 242,715 people with Covid-19 (55.6% female) and 276,317 controls (55.7% female) in 16 countries. Most were of moderate quality (71%). Only two were set in low-middle-income countries and few included children (18%). The longest mean follow-up time was 419.8 (standard deviation 49.4) days post-diagnosis. The relative risk (RR) of experiencing persistent or new symptoms in cases compared with controls was 1.53 (95% CI: 1.50 to 1.56). The core outcomes with the highest increased risk were cardiovascular (RR 2.53 95% CI: 2.16 to 2.96), cognitive (RR 1.99; 95% CI: 1.82 to 2.17), and physical functioning (RR 1.85; 95% CI: 1.75 to 1.96). Conclusion: SARS-CoV-2 infection is associated with a higher risk of new or persistent symptoms when compared with controls that can last over a year following acute Covid-19. There is still a lack of robust studies set in lower resourced settings and current studies have high heterogeneity and potential misclassifications of cases and controls. Future research should explore the role of vaccination and different variants on the risk of developing Long Covid.

show abstract

Persistent chest pain following COVID‐19 infection – A scoping review

Kubrova,

Hallo‐Carrasco,

Klasova

et al. 2024

PM&R

View full text Add to dashboard Cite

IntroductionPersistent chest pain (PCP) following acute COVID‐19 infection is a commonly reported symptom with an unclear etiology, making its management challenging. This scoping review aims to address the knowledge gap surrounding the characteristics of PCP following COVID‐19, its causes, and potential treatments.ObjectiveTo assess the prevalence, causes, and potential treatments of PCP following COVID‐19 infection.DesignA scoping review of 64 studies, including observational (prospective, retrospective, cross‐sectional, case series, and case‐control) and one quasi‐experimental study, from databases including Embase, PubMed/MEDLINE, Cochrane CENTRAL, Google Scholar, Cochrane Database of Systematic Reviews, and Scopus.SettingStudies on patients with PCP following mild, moderate, and severe COVID‐19 infection.PatientsStudies that included patients of any age, with chest pain that persisted following acute COVID‐19 disease, irrespective of etiology or duration.InterventionsNot applicable.Main Outcome Measure(s)Prevalence, causes, and potential treatments of PCP following COVID‐19 infection.ResultsA total of 35 studies reported PCP symptoms following COVID‐19 (0.24‐76.6%) at an average follow‐up of three months or longer, 12 studies at 1‐3 months and 17 studies at less than one month follow‐up or not specified. PCP was common following mild ‐ severe COVID‐19 infection, and etiology was mostly not reported. Fourteen studies proposed potential etiologies including endothelial dysfunction, cardiac ischemia, vasospasm, myocarditis, cardiac arrhythmia, pneumonia, pulmonary embolism, postural tachycardia syndrome (POTS), or noted cardiac MRI (cMRI) changes. Evaluation methods included common cardiopulmonary tests, as well as less common tests such as flow‐mediated dilatation (FMD), cMRI, single‐photon emission computed tomography myocardial perfusion imaging (SPECT‐MPI), and cardiopulmonary exercise testing (CPET). Only one study reported a specific treatment (sulodexide).ConclusionsPCP is a prevalent symptom following COVID‐19 infection, with various proposed etiologies. Further research is needed to establish a better understanding of the causes and to develop targeted treatments for PCP following COVID‐19.This article is protected by copyright. All rights reserved.

show abstract

SPECT myocardial perfusion imaging identifies myocardial ischemia in patients with a history of COVID-19 without coronary artery disease

Cited by 11 publications

References 26 publications

The Provision of Dental Care to COVID-19 Survivors: A Concise Review

The Provision of Dental Care to COVID-19 Survivors: A Concise Review

Characterising Long Covid: a living systematic review update with controlled studies

Persistent chest pain following COVID‐19 infection – A scoping review

Contact Info

Product

Resources

About